Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Aug. 26, 2024
In
many
hematologic
malignancies,
the
adoptive
transfer
of
chimeric
antigen
receptor
(CAR)
T
cells
has
demonstrated
notable
success;
nevertheless,
further
improvements
are
necessary
to
optimize
treatment
efficacy.
Current
CAR-T
therapies
particularly
discouraging
for
solid
tumor
treatment.
The
immunosuppressive
microenvironment
tumors
affects
cells,
limiting
treatment's
effectiveness
and
safety.
Therefore,
enhancing
cell
infiltration
capacity
resolving
responses
within
could
boost
anti-tumor
effect.
Specific
strategies
include
structurally
altering
combined
with
targeted
therapy,
radiotherapy,
or
chemotherapy.
Overall,
monitoring
status
is
beneficial
in
investigating
viability
such
advancing
therapy.
Discover Oncology,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: Oct. 19, 2023
Abstract
Myeloid-derived
suppressor
cells
(MDSCs),
major
components
maintaining
the
immune
suppressive
microenvironment
in
lung
cancer,
are
relevant
to
invasion,
metastasis,
and
poor
prognosis
of
through
regulation
epithelial-mesenchymal
transition,
remodeling
microenvironment,
angiogenesis.
MDSCs
regulate
T-cell
functions
by
a
strong
immunosuppressive
promoting
tumor
invasion.
This
raises
question
whether
reversing
effect
on
T
can
improve
cancer
treatment.
To
understand
this
further,
review
explores
interactions
specific
mechanisms
different
subsets,
including
regulatory
cells,
helper
CD8
+
natural
killer
exhausted
as
part
microenvironment.
Second,
it
focuses
guiding
significance
confirmed
via
clinical
liquid
biopsy
tissue
that
MDSC
subsets
cancer.
Finally,
we
conclude
targeting
action
targets
or
signaling
pathways
help
suppress
exhaustion.
In
addition,
checkpoint
inhibitors
may
serve
new
approach
for
enhancing
efficiency
immunotherapy
targeted
therapy
future,
providing
better
comprehensive
options
Nature Communications,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: Sept. 13, 2023
Abstract
Chronic
infections
and
cancers
evade
the
host
immune
system
through
mechanisms
that
induce
T
cell
exhaustion.
The
heterogeneity
within
exhausted
CD8
+
pool
has
revealed
importance
of
stem-like
progenitor
(Tpex)
terminal
(Tex)
cells,
although
underlying
their
development
are
not
fully
known.
Here
we
report
High
Mobility
Group
Box
2
(HMGB2)
protein
expression
is
upregulated
sustained
in
HMGB2
critical
for
differentiation.
Through
epigenetic
transcriptional
programming,
identify
as
a
cell-intrinsic
regulator
differentiation
maintenance
Tpex
cells
during
chronic
viral
infection
tumors.
Despite
Hmgb2
−/−
expressing
TCF-1
TOX,
these
master
regulators
were
unable
to
sustain
long-term
survival
persistent
antigen.
Furthermore,
also
had
function
memory
after
acute
infection.
Our
findings
show
key
may
be
an
important
molecular
target
future
cell-based
immunotherapies.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: June 26, 2024
Abstract
Tumor
immune
microenvironment
(TIME)
consists
of
intra-tumor
immunological
components
and
plays
a
significant
role
in
tumor
initiation,
progression,
metastasis,
response
to
therapy.
Chimeric
antigen
receptor
(CAR)-T
cell
immunotherapy
has
revolutionized
the
cancer
treatment
paradigm.
Although
CAR-T
emerged
as
successful
for
hematologic
malignancies,
it
remains
conundrum
solid
tumors.
The
heterogeneity
TIME
is
responsible
poor
outcomes
against
advancement
highly
sophisticated
technology
enhances
our
exploration
from
multi-omics
perspective.
In
era
machine
learning,
studies
could
reveal
characteristics
its
resistance
mechanism.
Therefore,
clinical
efficacy
tumors
be
further
improved
with
strategies
that
target
unfavorable
conditions
TIME.
Herein,
this
review
seeks
investigate
factors
influencing
formation
propose
improving
effectiveness
through
perspective,
ultimate
goal
developing
personalized
therapeutic
approaches.
Journal of Translational Medicine,
Journal Year:
2024,
Volume and Issue:
22(1)
Published: July 30, 2024
Circular
RNAs
(circRNAs)
have
been
implicated
in
the
development
and
progression
of
gastric
cancer
(GC).
However,
it
remains
unclear
whether
dysregulated
circRNA
affects
immune
escape
efficacy
immunotherapy
GC.
Our
aim
is
to
investigate
molecular
mechanism
affecting
GC
identify
effective
therapeutic
targets.
Molecular Cancer,
Journal Year:
2024,
Volume and Issue:
23(1)
Published: Aug. 26, 2024
In
many
hematologic
malignancies,
the
adoptive
transfer
of
chimeric
antigen
receptor
(CAR)
T
cells
has
demonstrated
notable
success;
nevertheless,
further
improvements
are
necessary
to
optimize
treatment
efficacy.
Current
CAR-T
therapies
particularly
discouraging
for
solid
tumor
treatment.
The
immunosuppressive
microenvironment
tumors
affects
cells,
limiting
treatment's
effectiveness
and
safety.
Therefore,
enhancing
cell
infiltration
capacity
resolving
responses
within
could
boost
anti-tumor
effect.
Specific
strategies
include
structurally
altering
combined
with
targeted
therapy,
radiotherapy,
or
chemotherapy.
Overall,
monitoring
status
is
beneficial
in
investigating
viability
such
advancing
therapy.
